Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year
Filters applied: . Clear all
Page 1
Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
Attrill GH, Owen CN, Ahmed T, Vergara IA, Colebatch AJ, Conway JW, Nahar KJ, Thompson JF, Pires da Silva I, Carlino MS, Menzies AM, Lo S, Palendira U, Scolyer RA, Long GV, Wilmott JS. Attrill GH, et al. Among authors: nahar kj. J Immunother Cancer. 2022 Jun;10(6):e004771. doi: 10.1136/jitc-2022-004771. J Immunother Cancer. 2022. PMID: 35688560 Free PMC article.